Clinical trials: Controlled Hypertension
Hypertension (HTN)
WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control
The WEARABLE-BP study will evaluate the clinical value of obtaining continual measurements using the Aktiia G1 Optical Blood Pressure Monitoring (OBPM) device in hypertensive patients, compared to using a traditional upper arm…
- Trial name
- WEARABLE-BP (NCT07523269)
- Testing
- Aktiia G1 BP monitor for 12 months, Traditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Aktiia SA
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Uncontrolled or Resistant Hypertension
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension.
- Trial name
- NCT07708441
- Testing
- HRS-1780 tablet
- Where
- 2 sites in China
- Volunteers
- 914 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Essential Hypertension
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
- Trial name
- NCT06716970
- Testing
- QR12000 75mg, QR12000 150mg, Sacubitril/valsartan 200mg
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Hypertension
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic…
- Trial name
- NCT00171054
- Testing
- Valsartan 320 mg, Amlodipine 10 mg, Hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 125 people
- Sponsor
- Novartis
Pulmonary Hypertension
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
- Trial name
- MELODY-1 (NCT02070991)
- Testing
- Macitentan
- Where
- 32 sites in United States, Austria and 9 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hypertension
Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
Hypertension is one of the most important preventable contributors to disease and death in the United States and represents the most common condition seen in the primary care setting.
- Trial name
- PGEN for HTN (NCT02988245)
- Testing
- Geneticure Panel for HTN therapy, JNC-8
- Where
- 15 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Geneticure, LLC
Essential Hypertension
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week…
- Trial name
- NCT06500689
- Testing
- Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil
- Where
- 40 sites in China
- Volunteers
- 366 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Essential Hypertension
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
- Trial name
- NCT06643819
- Testing
- Sacubitril∙Valsartan(dose maintenance), Sacubitril∙Valsartan(dose increasing), Valsartan
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and…
- Trial name
- NCT00923611
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Arterial Hypertension
An Analysis of Diabetes Control in Puerto Rico
Project: An analysis of Diabetes Control in Puerto Rico Hypothesis: This project seeks to determine the causes for: i) poor adherence to prescribed treatment by patients, ii) low compliance by providers with national guidelines…
- Conditions
- Diabetes Mellitus, Arterial Hypertension, Hypercholesterolemia
- Trial name
- NCT01117831
- Testing
- Epidemiological intervention
- Volunteers
- 600 people
- Sponsor
- Center for Diabetes Control, Inc.
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Hypertension
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor.
- Trial name
- NCT00351130
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Albuminuria, Chronic Kidney Diseases
Evaluation of the Accuracy and Usability of the Minuteful - Kidney Urine Analysis Test System in the Lay User Hands
The purpose of this study was to collect additional performance and clinical data on the Minuteful - Kidney test device (previously "ACR | U.S. Urine Analysis Test System"), following the original data collection (NCT04626271).
- Conditions
- Albuminuria, Chronic Kidney Diseases, Diabetes, Hypertension
- Trial name
- NCT05838872
- Testing
- Minuteful - Kidney Urine Analysis Test System
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Healthy.io Ltd.